Taysha Gene Therapies (NASDAQ: TSHA) R&D chief sells 200,000 shares under plan

Rhea-AI Filing Summary

Taysha Gene Therapies, Inc. director and officer Nagendran Sukumar reported an open-market sale of 200,000 shares of common stock on July 10, 2026 at a weighted average price of $6.24 per share. The shares were sold in multiple trades between $5.99 and $6.52 per share under a Rule 10b5-1 trading plan adopted on June 11, 2025. Following the transaction, Sukumar holds 936,410 shares of common stock directly.

Insights

Equity ownership analyst

Planned insider sale of 200,000 TSHA shares, with sizable holdings retained.

President and Head of R&D Nagendran Sukumar executed an open-market sale of 200,000 common shares of Taysha Gene Therapies, Inc. at a weighted average price of $6.24 per share on July 10, 2026. Trades occurred within a price range of $5.99–$6.52 per share.

The sale was carried out under a pre-established Rule 10b5-1 trading plan adopted on June 11, 2025, indicating it was scheduled in advance rather than opportunistic. After the sale, Sukumar continues to hold 936,410 shares directly, maintaining substantial equity exposure to the company.

Insider Trade Summary 10b5-1

Net Seller: 200,000 shares

Net Sell 1 txn

Insider Nagendran Sukumar

Role President and Head of R&D

Sold 200,000 shs ($1.25M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	200,000	$6.24	$1.25M

Holdings After Transaction: Common Stock — 936,410 shares (Direct)

Footnotes (2)

1. F1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 200,000 shares Weighted average sale price: $6.24 per share Post-transaction holdings: 936,410 shares +2 more

5 metrics

Shares sold 200,000 shares Open-market sale of common stock on July 10, 2026

Weighted average sale price $6.24 per share Average price across multiple sale transactions

Post-transaction holdings 936,410 shares Common stock held directly by Nagendran Sukumar after the sale

Sale price range low $5.99 per share Lowest price in the reported sale range

Sale price range high $6.52 per share Highest price in the reported sale range

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale

3 terms

Rule 10b5-1 trading plan regulatory

"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price. These shares were sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action":"open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 06:55 PM Accepted by SEC EDGAR 07/10/2026 - 06:54 PM Learn about SEC filing dates

FAQ

How many TSHA shares did Nagendran Sukumar sell in this Form 4 filing?

Nagendran Sukumar sold 200,000 shares of Taysha Gene Therapies, Inc. common stock. The sale was reported as an open-market transaction executed on July 10, 2026 at a weighted average price of $6.24 per share.

What price did TSHA insider Nagendran Sukumar receive for the shares sold?

The reported weighted average sale price was $6.24 per share. According to the filing, the 200,000 shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 per share, inclusive.

How many TSHA shares does Nagendran Sukumar hold after this transaction?

Following the sale, Nagendran Sukumar holds 936,410 shares of Taysha Gene Therapies, Inc. common stock. These shares are reported as being held directly, reflecting his remaining ownership position after the disclosed transaction.

Was the TSHA share sale by Nagendran Sukumar under a Rule 10b5-1 plan?

Yes. The filing states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Nagendran Sukumar on June 11, 2025, indicating the sales were pre-arranged rather than discretionary.

What role does TSHA insider Nagendran Sukumar hold at Taysha Gene Therapies?

Nagendran Sukumar is identified as both a director and an officer of Taysha Gene Therapies, Inc., serving as President and Head of R&D, according to the Form 4 reporting this stock sale.

What trading range did TSHA shares sell at in Sukumar’s reported transaction?

The filing notes that Sukumar’s 200,000 TSHA shares were sold in multiple trades at prices ranging from $5.99 to $6.52 per share, with a reported weighted average price of $6.24.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nagendran Sukumar

(Last) (First) (Middle)

C/O TAYSHA GENE THERAPIES, INC.

3000 PEGASUS PARK DRIVE, SUITE 1430

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Taysha Gene Therapies, Inc. [ TSHA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and Head of R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2026		S(1)		200,000	D	$6.24(2)	936,410	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Kamran Alam, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)